What to Expect From the Upcoming Dialogue IPO

The upcoming Dialogue IPO is set to be a big one, as Canadian investors look for more telemedicine options on the TSX.

Initial Public Offering (IPO) concept image, businessman selecting stock trading interface

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The telemedicine space is booming right now.

Vancouver-based Well Health Technologies has provided investors with a near five-bagger over the past year. Other U.S. players like Teladoc have similarly seen impressive stock price appreciation.

Accordingly, investors are eyeing what could be a highly sought-after IPO in Canada. It’s expected that Montreal-based Dialogue Health Technologies Inc. will go public shortly.

Similar to its aforementioned peers, the company operates in the telemedicine space. Dialogue designs specialized software solutions for telemedicine visits. The offerings include a mobile-based application that links doctors and patients.

Indeed, there’s higher demand than ever for this type of innovation in the healthcare sector, especially in light of the recent pandemic. However, investors seem to be bullish on the potential for a transformative, structural change to a traditional in-person industry. Indeed, the tentacles of technology are far-reaching today.

So, let’s look at what the IPO details are, and why investors are getting excited right now.

Dialogue IPO significantly oversubscribed

Having a vastly oversubscribed IPO is a good thing. Indeed, in Dialogue’s case, investors appear willing to line up around the block for these shares.

The company had to increase its initial public offering to $12 a share. This comes after receiving an overwhelming response from investors during the company’s marketing period.

Dialogue set out with an initial offering range between $9 and $12 a share. The amount the company wanted to raise was $100 million, and it received orders encompassing $1 billion. Indeed, any IPO that is 10 times oversubscribed is a hot one. Thus, there’s some speculation this IPO could open much higher upon the open of public trading. Dialogue has a consortium of big Canadian banks leading the deal and looks to be ready to hit the market soon.

Should investors buy in?

As of right now, Dialogue’s oversubscribed IPO looks like it could be the best-performing one in Canada in a while — at least, based on the initial data put forward.

Dialogue’s red herring prospectus reveals that the company has experienced a substantial amount of growth due to the ongoing pandemic. In 2020, this company’s online health service segment generated revenue of $29 million. This represented a three-fold increase from $10 million the year prior. It now provides this service to 2.5 million Canadians via four top Canadian group insurers.

This company is engaged in the provision of occupational health and safety services. Furthermore, it purchased an employee-assistance-program seller based in Canada. These two takeovers have been instrumental in strengthening Dialogue’s top line. In 2020, Dialogue’s annual recurring revenue stood at $60 million at the beginning of this year.

Indeed, these acquisitions have been a major boost for the company’s long-term top line. Furthermore, following the acquisitions, it appears that there’s ample growth on the horizon.

As far as IPOs go, this is one I’ll have my eye on. I would highly recommend investors add this stock to their watch list, if they’re not anticipating getting in early.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health.

More on Tech Stocks

A worker uses a double monitor computer screen in an office.
Tech Stocks

Why Shopify Stock Sold Off Last Week

Shopify (TSX:SHOP) sold off heavily last week. A bad earnings release may have been the culprit.

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Tech Stocks

2 Phenomenal Growth Stocks Down 30-60% That Could Rally in the Next Bull Market

Is it time to buy growth stocks? The worst of the interest rate hike and inflation is over, and now…

Read more »

stock market
Tech Stocks

2 Best Tech Stocks to Buy Before the Next Bull Market

Tech stocks such as Roku and Nuvei can help long-term investors generate outsized gains in 2023 and beyond.

Read more »

Wireless technology
Tech Stocks

Tucows Stock Trades Near its 6-Year Low: Is it a Buy?  

Tucows stock fell 63% in the tech stock sell-off and has failed to show any recovery. Is this domain and…

Read more »

Male IT Specialist Holds Laptop and Discusses Work with Female Server Technician. They're Standing in Data Center, Rack Server Cabinet with Cloud Server Icon and Visualization
Tech Stocks

Is Converge Stock a Buy?

A relatively new tech stock could soar higher with the pause in rate hikes, although a resumption of the cycle…

Read more »

online shopping
Tech Stocks

Up by 25%: Is Shopify Stock Finally a Buy in 2023?

The strong rebound in the TSX’s top tech stock remains uncertain. Investors will have to wait before it delivers stellar…

Read more »

Businessman holding AI cloud
Tech Stocks

2 TSX Tech Stocks Innovating Hard in AI

Shopify (TSX:SHOP) stock and another intriguing Canadian gem make good use of AI technologies.

Read more »

worry concern
Tech Stocks

Shopify Stock: Incredible Bargain or Deceptive Trap?

Shopify has quickly shifted from a market darling to something else. Is it a safe buy or risqué bet?

Read more »